Acrobiosystems Co

Acrobiosystems Co Revenue per Employee

The Revenue per Employee of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 1.40 M CNY. In the previous year, Revenue per Employee was 1.08 M CNY — a change of 29.94% (higher).

Revenue per Employee

1.40 MCNY

YoY

29.94%

Last updated:

Revenue per Employee of Acrobiosystems Co is 2025 1.40 M CNY. Revenue per Employee of Acrobiosystems Co was 2024 1.08 M CNY. It decreases by 29.94% higher compared to the previous year.

The Acrobiosystems Co Revenue per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Employee
Date
Revenue per Employee
Jan 1, 2018
116,987.60 CNY
Jan 1, 2019
173,020.15 CNY
Jan 1, 2020
412,594.00 CNY
Jan 1, 2021
644,870.52 CNY
Jan 1, 2022
794,691.62 CNY
Jan 1, 2023
910,641.98 CNY
Jan 1, 2024
1.08 M CNY
Jan 1, 2025
1.40 M CNY
The Acrobiosystems Co Revenue per Employee history
YEARRevenue per EmployeeYoY
1.40 MCNY+29.94%
1.08 MCNY+18.65%
910,641.98CNY+14.59%
794,691.62CNY+23.23%
644,870.52CNY+56.30%
412,594.00CNY+138.47%
173,020.15CNY+47.90%
116,987.60CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Revenue per Employee of Acrobiosystems Co is 1.40 M CNY in 2025.

Revenue per Employee of Acrobiosystems Co changed from 1.08 M CNY to 1.40 M CNY, representing a 29.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Employee Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Revenue per employee measures workforce productivity by dividing total revenue by the number of employees. Higher values indicate more efficient operations.

Revenue per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Revenue per Employee's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co